Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest.

Abstract:

:While many antibody therapeutics are formulated at low concentration (~10-20 mg/mL) for intravenous administration, high concentration (> 100 mg/mL) formulations may be required for subcutaneous delivery in certain clinical indications. For such high concentration formulations, product color is more apparent due to the higher molecular density across a given path-length. Color is therefore a product quality attribute that must be well-understood and controlled, to demonstrate process consistency and enable clinical trial blinding. Upon concentration of an IgG4 product at the 2000 L manufacturing scale, variability in product color, ranging from yellow to red, was observed. A small-scale experimental model was developed to assess the effect of processing conditions (medium composition and harvest conditions) on final bulk drug substance (BDS) color. The model was used to demonstrate that, for two distinct IgG4 products, red coloration occurred only in the presence of disulfide reduction-mediated antibody dissociation. The red color-causing component was identified as vitamin B 12, in the hydroxocobalamin form, and the extent of red color was correlated with the cobalt (vitamin B 12) concentration in the final pools. The intensity of redness in the final BDS was modulated by changing the concentration of vitamin B 12 in the cell culture media.

journal_name

MAbs

journal_title

mAbs

authors

Derfus GE,Dizon-Maspat J,Broddrick JT,Velayo AC,Toschi JD,Santuray RT,Hsu SK,Winter CM,Krishnan R,Amanullah A

doi

10.4161/mabs.28257

subject

Has Abstract

pub_date

2014-05-01 00:00:00

pages

679-88

issue

3

eissn

1942-0862

issn

1942-0870

pii

28257

journal_volume

6

pub_type

杂志文章

相关文献

mAbs文献大全
  • Metal ion interactions with mAbs: Part 1.

    abstract::Fragmentation in the hinge region of an IgG1 monoclonal antibody (mAb) can affect product stability, potentially causing changes in potency and efficacy. Metals ions, such as Cu(2+), can bind to the mAb and undergo hydrolysis or oxidation, which can lead to cleavage of the molecule. To better understand the mechanism ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1062193

    authors: Glover ZK,Basa L,Moore B,Laurence JS,Sreedhara A

    更新日期:2015-01-01 00:00:00

  • Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.

    abstract::The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of sy...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1685350

    authors: Wang F,Tsai JC,Davis JH,Chau B,Dong J,West SM,Hogan JM,Wheeler ML,Bee C,Morishige W,Cayton T,David-Brown D,Zhang C,Kozhich A,Sproul T,Dollinger G,Rajpal A,Strop P

    更新日期:2020-01-01 00:00:00

  • Certolizumab pegol.

    abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.2.11271

    authors: Goel N,Stephens S

    更新日期:2010-03-01 00:00:00

  • Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library.

    abstract::A costimulatory signal is required for the full activation of T cells, in addition to the antigen-specific signal via the T cell receptor. The inducible costimulator, ICOS is one of the costimulatory molecules that play an essential role in this process, particularly in the expansion or the development of effector T c...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.5.9633

    authors: Maeda M,Ito Y,Hatanaka T,Hashiguchi S,Torikai M,Nakashima T,Sugimura K

    更新日期:2009-09-01 00:00:00

  • Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.

    abstract::The current standard treatment for acute myeloid leukemia (AML) is chemotherapy based on cytarabine and daunorubicine (7 + 3), but it discriminates poorly between malignant and benign cells. Dose-limiting off‑target effects and intrinsic drug resistance result in the inefficient eradication of leukemic blast cells and...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007818

    authors: Fitting J,Blume T,Ten Haaf A,Blau W,Gattenlöhner S,Tur MK,Barth S

    更新日期:2015-01-01 00:00:00

  • Non-neutralizing antibodies increase endogenous circulating Ang1 levels.

    abstract::Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level was significantly increased in cynomolgus monkeys treated with non-neutralizing anti-Ang1 antibodies. Improving the an...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1521130

    authors: Zheng C,Toth J,Bigwarfe T,MacDougall M,Jerath K,Bovat K,Smith J,Sun P,Hayes D,Fryer R,Singh S,Kroe-Barrett R

    更新日期:2018-11-01 00:00:00

  • Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach.

    abstract::Antibodies are routinely used to study the activity of transcription factors, using various in vitro and in vivo approaches such as electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, genome-wide method analysis coupled with next generation sequencing, or mass spectrometry. More recently, a new ap...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451288

    authors: Fontaine FR,Goodall S,Prokop JW,Howard CB,Moustaqil M,Kumble S,Rasicci DT,Osborne GW,Gambin Y,Sierecki E,Jones ML,Zuegg J,Mahler S,Francois M

    更新日期:2018-05-01 00:00:00

  • Cysteinylation of a monoclonal antibody leads to its inactivation.

    abstract::Post-translational modifications can have a signification effect on antibody stability. A comprehensive approach is often required to best understand the underlying reasons the modification affects the antibody's potency or aggregation state. Monoclonal antibody 001 displayed significant variation in terms of potency,...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1160179

    authors: McSherry T,McSherry J,Ozaeta P,Longenecker K,Ramsay C,Fishpaugh J,Allen S

    更新日期:2016-05-01 00:00:00

  • Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.

    abstract::Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1770669

    authors: Xu J,Xu X,Huang C,Angelo J,Oliveira CL,Xu M,Xu X,Temel D,Ding J,Ghose S,Borys MC,Li ZJ

    更新日期:2020-01-01 00:00:00

  • IgE immunotherapy: a novel concept with promise for the treatment of cancer.

    abstract::The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the I...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.27029

    authors: Josephs DH,Spicer JF,Karagiannis P,Gould HJ,Karagiannis SN

    更新日期:2014-01-01 00:00:00

  • Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.

    abstract::Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a treatment medication for METH abuse. In these studies, we present the preclinical characterization that provided predictive evidence that ch-mAb7F9 may be safe a...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.27620

    authors: Stevens MW,Tawney RL,West CM,Kight AD,Henry RL,Owens SM,Gentry WB

    更新日期:2014-03-01 00:00:00

  • Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.

    abstract::Neutralizing antibody responses to the surface glycoproteins of enveloped viruses play an important role in immunity. Many of these glycoproteins, including the severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) protein form trimeric units in the membrane of the native virion. There is substantial expe...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.1.10788

    authors: Berry JD,Hay K,Rini JM,Yu M,Wang L,Plummer FA,Corbett CR,Andonov A

    更新日期:2010-01-01 00:00:00

  • Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein.

    abstract::Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody spec...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1843754

    authors: Velappan N,Micheva-Viteva S,Adikari SH,Waldo GS,Lillo AM,Bradbury ARM

    更新日期:2020-01-01 00:00:00

  • Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

    abstract::The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients exp...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.6.17955

    authors: Koefoed K,Steinaa L,Søderberg JN,Kjær I,Jacobsen HJ,Meijer PJ,Haurum JS,Jensen A,Kragh M,Andersen PS,Pedersen MW

    更新日期:2011-11-01 00:00:00

  • Thermodynamic and structural characterization of an antibody gel.

    abstract::Although extensively studied, protein-protein interactions remain highly elusive and are of increasing interest in drug development. We show the assembly of a monoclonal antibody, using multivalent carboxylate ions, into highly-ordered structures. While the presence and function of similar structures in vivo are not k...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.23183

    authors: Esue O,Xie AX,Kamerzell TJ,Patapoff TW

    更新日期:2013-03-01 00:00:00

  • Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.

    abstract::Monoclonal antibody (mAb) candidates from high-throughput screening or binding affinity optimization often contain mutations leading to liabilities for further development of the antibody, such as aggregation-prone regions and lack of solubility. In this work, we optimized a candidate integrin α11-binding mAb for deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1475871

    authors: Jetha A,Thorsteinson N,Jmeian Y,Jeganathan A,Giblin P,Fransson J

    更新日期:2018-08-01 00:00:00

  • The making of bispecific antibodies.

    abstract::During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibo...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2016.1268307

    authors: Brinkmann U,Kontermann RE

    更新日期:2017-02-01 00:00:00

  • A method to confer Protein L binding ability to any antibody fragment.

    abstract::Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is abl...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1116657

    authors: Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey N

    更新日期:2016-01-01 00:00:00

  • Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individual.

    abstract::The cervical mucosa of women who are highly exposed to HIV-1, yet remain persistently seronegative (HEPS), presents a unique opportunity to study the dynamics of an immune compartment potentially capable of preventing HIV-1 infection. Herein, we provide a detailed characterization of the immunoglobulin repertoire of c...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.2.14858

    authors: Gaudet RG,Breden F,Plummer F,Berry JD

    更新日期:2011-03-01 00:00:00

  • High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer.

    abstract::The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.26712

    authors: Reusch D,Haberger M,Kailich T,Heidenreich AK,Kampe M,Bulau P,Wuhrer M

    更新日期:2014-01-01 00:00:00

  • Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.

    abstract::Monoclonal antibodies constitute a robust class of therapeutic proteins. Their stability, resistance to stress conditions and high solubility have allowed the successful development and commercialization of over 40 antibody-based drugs. Although mAbs enjoy a relatively high probability of success compared with other t...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25269

    authors: Yang X,Xu W,Dukleska S,Benchaar S,Mengisen S,Antochshuk V,Cheung J,Mann L,Babadjanova Z,Rowand J,Gunawan R,McCampbell A,Beaumont M,Meininger D,Richardson D,Ambrogelly A

    更新日期:2013-09-01 00:00:00

  • Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins.

    abstract::Gel microdroplet - fluorescence activated cell sorting (GMD-FACS) is an innovative high throughput screening platform for recombinant protein libraries, and we show here that GMD-FACS can overcome many of the limitations associated with conventional screening methods for antibody libraries. For example, phage and cell...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2017.1381812

    authors: Fang Y,Chu TH,Ackerman ME,Griswold KE

    更新日期:2017-11-01 00:00:00

  • Antibodies to watch in 2010.

    abstract::Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.1.10677

    authors: Reichert JM

    更新日期:2010-01-01 00:00:00

  • PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies.

    abstract::High titer (>10 g/L) monoclonal antibody (mAb) cell culture processes are typically achieved by maintaining high viable cell densities over longer culture durations. A corresponding increase in the solids and sub-micron cellular debris particle levels are also observed. This higher burden of solids (≥15%) and sub-micr...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007824

    authors: McNerney T,Thomas A,Senczuk A,Petty K,Zhao X,Piper R,Carvalho J,Hammond M,Sawant S,Bussiere J

    更新日期:2015-01-01 00:00:00

  • Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

    abstract::MPDL3280A is a human monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1), and exerts anti-tumor activity mainly by blocking PD-L1 interaction with programmed cell death-1 (PD-1) and B7.1. It is being investigated as a potential therapy for locally advanced or metastatic malignancies. The purpose ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1136043

    authors: Deng R,Bumbaca D,Pastuskovas CV,Boswell CA,West D,Cowan KJ,Chiu H,McBride J,Johnson C,Xin Y,Koeppen H,Leabman M,Iyer S

    更新日期:2016-01-01 00:00:00

  • The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

    abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1016692

    authors: Brady LJ,Velayudhan J,Visone DB,Daugherty KC,Bartron JL,Coon M,Cornwall C,Hinckley PJ,Connell-Crowley L

    更新日期:2015-01-01 00:00:00

  • The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen.

    abstract::A dual-specific, tetravalent immunoglobulin G-like molecule, termed dual variable domain immunoglobulin (DVD-Ig™), is engineered to block two targets. Flexibility modulates Fc receptor and complement binding, but could result in undesirable cross-linking of surface antigens and downstream signaling. Understanding the ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24258

    authors: Correia I,Sung J,Burton R,Jakob CG,Carragher B,Ghayur T,Radziejewski C

    更新日期:2013-05-01 00:00:00

  • A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

    abstract::The critical role played by IgE in allergic asthma is well-documented and clinically precedented, but some patients in whom IgE neutralization may still offer clinical benefit are excluded from treatment with the existing anti-IgE therapy, omalizumab, due to high total IgE levels or body mass. In this study, we sought...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28394

    authors: Cohen ES,Dobson CL,Käck H,Wang B,Sims DA,Lloyd CO,England E,Rees DG,Guo H,Karagiannis SN,O'Brien S,Persdotter S,Ekdahl H,Butler R,Keyes F,Oakley S,Carlsson M,Briend E,Wilkinson T,Anderson IK,Monk PD,von Wachenfe

    更新日期:2014-05-01 00:00:00

  • Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.

    abstract::Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of D...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1603024

    authors: Seifert O,Rau A,Beha N,Richter F,Kontermann RE

    更新日期:2019-07-01 00:00:00

  • Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

    abstract::Therapeutic antibodies continue to develop as an emerging drug class, with a need for preclinical tools to better predict in vivo characteristics. Transgenic mice expressing human neonatal Fc receptor (hFcRn) have potential as a preclinical pharmacokinetic (PK) model to project human PK of monoclonal antibodies (mAbs)...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1193660

    authors: Avery LB,Wang M,Kavosi MS,Joyce A,Kurz JC,Fan YY,Dowty ME,Zhang M,Zhang Y,Cheng A,Hua F,Jones HM,Neubert H,Polzer RJ,O'Hara DM

    更新日期:2016-08-01 00:00:00